Abaloparatide, a selective activator of the parathyroid hormone receptor, has recently been shown to reduce fractures in postmenopausal women with osteoporosis.
Now new research shows that abaloparatide increases bone mass in rats whose ovaries have been removed by stimulating bone formation, without effects on bone resorption.
"These preclinical data support the continued development of abaloparatide as a treatment to reduce fracture risk in patients with osteoporosis," wrote the authors of the Journal of Bone and Mineral Research study.
Aurore Varela et al, One Year of Abaloparatide, a Selective Activator of the PTH1 Receptor, Increased Bone Formation and Bone Mass in Osteopenic Ovariectomized Rats Without Increasing Bone Resorption, Journal of Bone and Mineral Research
(2016). DOI: 10.1002/jbmr.3003
Research reveals how novel osteoporosis drug increases bone mass (2016, October 19)
retrieved 2 December 2020
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.